MannKind Corporation (MNKD)
4.63
-0.03 (-0.64%)
At close: Apr 14, 2025, 3:59 PM
4.66
0.82%
After-hours: Apr 14, 2025, 07:52 PM EDT
-0.64% (1D)
| Bid | 4.51 |
| Market Cap | 1.41B |
| Revenue (ttm) | 285.5M |
| Net Income (ttm) | 27.59M |
| EPS (ttm) | 0.1 |
| PE Ratio (ttm) | 46.25 |
| Forward PE | 37.03 |
| Analyst | Buy |
| Ask | 4.78 |
| Volume | 1,549,204 |
| Avg. Volume (20D) | 2,130,750 |
| Open | 4.68 |
| Previous Close | 4.66 |
| Day's Range | 4.61 - 4.71 |
| 52-Week Range | 3.97 - 7.63 |
| Beta | 1.21 |
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a licens...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 28, 2004
Employees 403
Stock Exchange NASDAQ
Ticker Symbol MNKD
Website https://www.mannkindcorp.com
Analyst Forecast
According to 6 analyst ratings, the average rating for MNKD stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 83.78% from the latest price.
Stock ForecastsNext Earnings Release
MannKind Corporation is scheduled to release its earnings on May 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+8.73%
MannKind shares are trading higher after Wells Far...
Unlock content with
Pro Subscription
7 months ago
+9.67%
MannKind shares are trading higher after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $10 to $12.
